arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

EXELIXIS, INC.

EXEL
$68.70 ▼ -4.07 (-5.59%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
69 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
90
Health
Excellent
Bullish
auto_awesome

Analytical Summary

EXELIXIS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $17.0B
Dividend Yield —
Revenue Growth 10.2% ↘
Op. Margin 40.8% ↗
ROIC 11.6% ↗
FCF / Share $1.12 ↘
Trailing P/E 78.1x
Price / Book 9.2x
FCF Yield 1.6%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

69-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$658.70M
↑ +10.2% —
Net Income Profit after all expenses
$218.09M
↑ +12.7% —
Operating Margin Operating profit as % of sales
40.8%
↑ +3.1% 92th
FCF / Share Free cash flow per share
$1.12
↓ -6.3% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
94
Returns ↑
95
Cash Quality ↓
70

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 18 years · 69 quarters